Trial Profile
A PROTOCOL TO MONITOR FROM BIRTH TO AGE 15 MONTHS THE NEUROLOGICAL DEVELOPMENT OF INFANTS WITH EXPOSURE IN-UTERO IN TANEZUMAB CLINICAL STUDIES AT ALL INVESTIGATIONAL SITES
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jun 2021
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary) ; Celecoxib; Diclofenac; Naproxen
- Indications Back pain; Cancer pain; Musculoskeletal pain
- Focus Adverse reactions; Registrational
- Sponsors Pfizer
- 14 Aug 2020 Status changed from active, no longer recruiting to completed.
- 20 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 03 Dec 2018 Planned End Date changed from 1 Apr 2022 to 4 Apr 2022.